m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00714)
Target Name Krueppel-like factor 2 (KLF2)
Synonyms
Lung krueppel-like factor
    Click to Show/Hide
Gene Name KLF2
Chromosomal Location 19p13.11
Family Krueppel C2H2-type zinc-finger protein family
Function
Transcription factor that binds to the CACCC box in the promoter of target genes such as HBB/beta globin or NOV and activates their transcription. Might be involved in transcriptional regulation by modulating the binding of the RARA nuclear receptor to RARE DNA elements.
    Click to Show/Hide
Gene ID 10365
Uniprot ID
KLF2_HUMAN
HGNC ID
HGNC:6347
Ensembl Gene ID
ENSG00000127528
KEGG ID
hsa:10365
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
KLF2 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by FTO
Cell Line B16F10 cell line Mus musculus
Treatment: FTO knockout B16F10 cells
Control: B16F10 cells
 GSE134388
Regulation
logFC: -1.68E+00
p-value: 3.25E-02
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary FTO overexpression significantly upregulated the mRNA and protein levels of VCAM-1 and ICAM-1, downregulated those of Krueppel-like factor 2 (KLF2) and eNOS, and strongly attenuated the atorvastatin-mediated induction of KLF2 and eNOS expression. FTO could serve as a novel molecular target to modulate endothelial function in vascular diseases.
Target Regulation Down regulation
Responsed Disease Vascular diseases ICD-11: BE2Z
 Disease Info 
Responsed Drug Atorvastatin Approved
 Drug Info 
In-vitro Model THP-1 Childhood acute monocytic leukemia Homo sapiens CVCL_0006
HUVEC-C Normal Homo sapiens CVCL_2959
HEK293T Normal Homo sapiens CVCL_0063
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line LX2 cell line Homo sapiens
Treatment: shMETTL3 LX2 cells
Control: shLuc LX2 cells
 GSE207909
Regulation
logFC: -1.15E+00
p-value: 3.23E-14
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary METTL3 promotes translation of SPHK2 mRNA via an m6A-YTHDF1-dependent manner. Functionally, SPHK2 facilitates GC cell proliferation, migration and invasion by inhibiting Krueppel-like factor 2 (KLF2) expression.
Target Regulation Down regulation
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
Cell Process Cell proliferation
Cell migration
Cell invasion
Gastric cancer [ICD-11: 2B72]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [2]
Response Summary METTL3 promotes translation of SPHK2 mRNA via an m6A-YTHDF1-dependent manner. Functionally, SPHK2 facilitates GC cell proliferation, migration and invasion by inhibiting Krueppel-like factor 2 (KLF2) expression.
Responsed Disease Gastric cancer [ICD-11: 2B72]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
Cell Process Cell proliferation
Cell migration
Cell invasion
Diseases of the circulatory system [ICD-11: BE2Z]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary FTO overexpression significantly upregulated the mRNA and protein levels of VCAM-1 and ICAM-1, downregulated those of Krueppel-like factor 2 (KLF2) and eNOS, and strongly attenuated the atorvastatin-mediated induction of KLF2 and eNOS expression. FTO could serve as a novel molecular target to modulate endothelial function in vascular diseases.
Responsed Disease Vascular diseases [ICD-11: BE2Z]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Target Regulation Down regulation
Responsed Drug Atorvastatin Approved
 Drug Info 
In-vitro Model THP-1 Childhood acute monocytic leukemia Homo sapiens CVCL_0006
HUVEC-C Normal Homo sapiens CVCL_2959
HEK293T Normal Homo sapiens CVCL_0063
Atorvastatin [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary FTO overexpression significantly upregulated the mRNA and protein levels of VCAM-1 and ICAM-1, downregulated those of Krueppel-like factor 2 (KLF2) and eNOS, and strongly attenuated the atorvastatin-mediated induction of KLF2 and eNOS expression. FTO could serve as a novel molecular target to modulate endothelial function in vascular diseases.
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Target Regulation Down regulation
Responsed Disease Vascular diseases ICD-11: BE2Z
 Disease Info 
In-vitro Model THP-1 Childhood acute monocytic leukemia Homo sapiens CVCL_0006
HUVEC-C Normal Homo sapiens CVCL_2959
HEK293T Normal Homo sapiens CVCL_0063
References
Ref 1 N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells. Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658. doi: 10.1161/ATVBAHA.121.317295. Epub 2022 Mar 17.
Ref 2 METTL3-mediated m(6)A methylation of SPHK2 promotes gastric cancer progression by targeting KLF2. Oncogene. 2021 Apr;40(16):2968-2981. doi: 10.1038/s41388-021-01753-1. Epub 2021 Mar 23.